학술논문
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
Document Type
ConferencePaper
Author
Brown, JR; Eichhorst, BF; Lamanna, N; O'Brien, SM; Tam, CS; Qiu, LQ; Kazmierczak, M; Jurczak, W; Zhou, KS; Simkovic, M; Mayer, J; Gillespie-Twardy, AL; Ferrajoli, A; Ganly, PS; Weinkove, R; Grosicki, S; Mital, A; Robak, T; Osterborg, A; Yimer, HA; Wang, MG; Salmi, T; Wang, LP; Li, J; Wu, K; Cohen, AC; Shadman, M
Source
BLOOD. 142
Subject
Language
English
English
English
ISSN
0006-4971